105 related articles for article (PubMed ID: 38723213)
1. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
Gregorio C; Spreafico M; D'Amico S; Sauta E; Asti G; Lanino L; Tentori CA; Platzbecker U; Haferlach T; Diez-Campelo M; Fenaux P; Komrokji R; Della Porta MG; Ieva F
JCO Clin Cancer Inform; 2024 May; 8():e2300205. PubMed ID: 38723213
[TBL] [Abstract][Full Text] [Related]
2. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Alessandrino EP; Porta MG; Malcovati L; Jackson CH; Pascutto C; Bacigalupo A; Teresa van Lint M; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Rambaldi A; Bosi A; Cazzola M;
Am J Hematol; 2013 Jul; 88(7):581-8. PubMed ID: 23606215
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
4. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
5. Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.
Cutler C
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):77-81. PubMed ID: 25696838
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study.
Chapchap EC; Kerbauy LN; Esteves I; Belucci TR; Rodrigues M; Kerbauy FR; de Souza Santos FP; Ribeiro AAF; Hamerschlak N
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13122. PubMed ID: 31257689
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.
Konuma T; Miyazaki Y; Uchida N; Ohashi K; Kondo T; Nakamae H; Takahashi S; Mori T; Ozawa Y; Kato C; Iwato K; Fukuda T; Ichinohe T; Atsuta Y; Ishiyama K;
Biol Blood Marrow Transplant; 2017 Jan; 23(1):75-80. PubMed ID: 27777139
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
14. On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.
Campidelli A; Robin M; Remen T; Luc A; Labussière-Wallet H; Dulery R; Srour M; Ceballos P; Forcade E; Nguyen-Quoc S; Furst S; Turlure P; Bay JO; Simand C; Marçais A; Daguindau E; Rubio MT; D'Aveni M
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):34-43. PubMed ID: 34456160
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
17. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
18. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.
Xu L; Chen H; Chen J; Han M; Huang H; Lai Y; Liu D; Liu Q; Liu T; Jiang M; Ren H; Song Y; Sun Z; Wang J; Wu D; Zhou D; Zou P; Liu K; Huang X
J Hematol Oncol; 2018 Mar; 11(1):33. PubMed ID: 29495966
[TBL] [Abstract][Full Text] [Related]
19. Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation.
Kaito S; Wada A; Adachi H; Konuma R; Kishida Y; Nagata A; Konishi T; Yamada Y; Kumagai T; Yoshifuji K; Mukae J; Akiyama M; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Ohashi K; Sakamaki H; Doki N
Ann Hematol; 2020 Jul; 99(7):1655-1665. PubMed ID: 32524200
[TBL] [Abstract][Full Text] [Related]
20. [Allogeneic transplantation for myelodysplastic syndromes: analyses of the Japanese registry data].
Ishiyama K
Rinsho Ketsueki; 2021; 62(4):289-298. PubMed ID: 33967154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
